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Abstract 
Renal involvement causing progressive chronic kidney disease (CKD) is present in 70% of 
patients with systemic AL amyloidosis at diagnosis. Chemotherapy that substantially 
suppresses free light chain (FLC) production is associated with improved patient survival, but 
its benefit in delaying the onset of renal replacement therapy among patients who present 
with established advanced CKD has not been studied. Of 1000 patients who were enrolled 
into the prospective UK AL amyloidosis chemotherapy (ALchemy) study, 84 patients had 
advanced amyloid-related CKD defined by an estimated glomerular filtration rate (eGFR) 
<20 ml/min/1.73 m2. We determined outcomes among these 84 patients in relation to 
response to chemotherapy evaluated at 3, 6 and 12 months from baseline. Median baseline 
eGFR was 10 ml/min/1.73 m2. Patients who achieved a dFLC response of ≥90% within 3 
months of baseline had significantly better overall survival (p=0.02), a prolonged time to 
dialysis (p=0.003), and a prolonged time to the composite endpoint of ‘death or dialysis’ 
(p<0.001) compared to those who achieved lesser degrees of clonal response at the same 
timepoint.  A delay beyond 3 months in achieving a ≥90% dFLC response was also 
associated with worse outcomes.  Cox regression analyses showed that achieving a dFLC 
response of ≥90% within 3 months of baseline was the only independent predictor of all three 
of these outcome measures (p<0.04).  Renal survival among patients with systemic AL 
amyloidosis who present with advanced CKD is strongly dependent upon the magnitude and 
speed with which the underlying hematologic disorder is suppressed by chemotherapy. 
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Introduction 
The amyloidoses are disorders of protein folding, in which a variety of proteins misfold and 
aggregate into amyloid fibrils that accumulate in tissues and disrupt organ function.1  
Immunoglobulin light chain (AL) amyloidosis is caused by deposition of fibrils derived from 
monoclonal immunoglobulin light chains and is the most common and serious type of systemic 
amyloidosis.2  Renal involvement is present in approximately 70% of patients with systemic 
AL amyloidosis at diagnosis, manifesting with nephrotic syndrome and progressive renal 
impairment.3  Progression to end-stage renal disease (ESRD) is one of the main determinants 
of morbidity in AL amyloidosis,4 whilst presence and severity of cardiac amyloidosis is the 
main determinant of mortality.5, 6 
Response to chemotherapy has been shown to be strongly and independently associated 
with both patient survival3 and renal outcomes in patients with AL amyloidosis.7, 8  Other 
factors associated with poor renal outcomes in those with renal AL amyloidosis include a low 
GFR and heavy proteinuria at diagnosis.7, 9  However, there are no data on whether 
chemotherapy can delay onset of renal replacement therapy in patients with AL amyloidosis 
who present with established advanced CKD and whether speed of clonal response influences 
renal outcome. 
The AL Amyloidosis Chemotherapy study (ALchemy) is a comprehensive prospective 
observational study opened in 2009 into which all patients newly diagnosed with AL 
amyloidosis at the UK National Amyloidosis Centre (NAC) are invited to participate.  We 
report here the renal and patient outcomes among all participants in ALchemy who had 
advanced CKD at the time of diagnosis (and entry to study) between 2009 and 2015 in relation 
to the speed and depth of the hematologic response to chemotherapy.   
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Results 
Baseline Characteristics and Patient Survival 
Baseline demographics and clinical characteristics of all 84 patients are listed in Table 1. The 
cohort was followed for a median of 16.3 months (range 0.4-68.0) from baseline.  Forty five 
of 84 patients had ‘renal isolated’ involvement and 39 had evidence of both cardiac and renal 
involvement (Figure 1).  Fifty-seven of 84 patients had renal histology performed and all 
biopsies showed extensive renal infiltration by amyloid; the only other notable pathology being 
hypertensive arteriosclerosis in 2 cases.  Median age at diagnosis in the whole cohort was 68 
years with an almost equal male to female ratio.  Median eGFR was 10 ml/min/1.73 m2 with a 
median 24 hour urinary protein leak of 6.2 grams.  Serum albumin was modestly reduced with 
a median of 31 g/L despite substantial proteinuria in the majority of cases.  Median NT-proBNP 
was 550 pMol/L with 32 patients having a concentration >1000 pmol/L (i.e., Mayo stage 3b 
disease).6   
A total of 47/84 (56%) patients from the whole cohort died with median time from 
baseline to death by Kaplan Meier analysis of 25.2 months (CI 9.4-41.1).  Thirty of 39 patients 
with cardio-renal syndrome (due to cardiac and renal involvement by amyloid) died and 17 of 
45 patients with ‘renal isolated’ amyloidosis died.  Median overall survival was significantly 
longer (49.2 months [CI 34.5-undefined]) among those with ‘renal isolated’ amyloidosis 
compared to those with cardio-renal syndrome (8.4 months [CI 4.7-22.9], p<0.001) (Figure 2).  
Cause of death among those with cardio-renal syndrome was invariably from progressive 
cardiac amyloidosis, and in those with renal isolated amyloidosis, was from ‘progressive 
amyloidosis’ in 9 cases, and from sepsis, cerebrovascular accident, and incarcerated femoral 
hernia in one case each.  In 5 cases the cause of death was unknown. 
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Chemotherapy 
Chemotherapy was planned in all 84 cases, but was actually administered to 78 patients.  
Reasons for non-administration of chemotherapy were patient death from progressive 
amyloidosis in 4/6 patients, and dialysis-dependence in 2 patients who did not have significant 
extra-renal amyloid.  Among those who did receive chemotherapy, 43 (55%) received 
bortezomib-based regimens first line, 22 (28%) received thalidomide-based regimens first line, 
and 13 (17%) received a first line regimen containing neither bortezomib nor thalidomide.  
Median (range) number of chemotherapy cycles administered first line was 4 (1-8) for each of 
bortezomib-based, thalidomide-based and non-bortezomib, non-thalidomide containing 
regimens.  No patient discontinued bortezomib therapy, but 1 patient discontinued thalidomide, 
and 1 patient discontinued non-bortezomib, non-thalidomide chemotherapy due to toxicity.  
As-treated analysis of the 78 patients who received chemotherapy showed a dFLC response at 
3 months of ≥90% in 15/43 (34%) who received bortezomib compared to 4/22 (18%) who 
received thalidomide (bortezomib vs thalidomide, p=0.09, Fisher’s exact test) and 2/13 (15%) 
who received neither drug first line (bortezomib vs neither bortezomib nor thalidomide, 
p=0.12, Fisher’s exact test).   
 
Overall survival (OS) in relation to response to chemotherapy 
Seventy-four patients were evaluable for dFLC response by consensus criteria (i.e., had a dFLC 
at baseline of >50mg/L). Of those 74 patients, 15 did not have a dFLC measurement at 3 
months, in 11 cases due to prior death, and were therefore excluded from the analysis of 
survival in relation to hematologic response at this timepoint.  Of the 11 patients who died, 6 
did so before receiving chemotherapy, 4 died from progressive amyloidosis and one died from 
chemotherapy-related complications (sepsis).  There was no significant difference in overall 
6 
 
survival between 26 evaluable patients who achieved a dFLC of <40mg/L within 3 months of 
baseline (median 49.2 months [CI 25.0–undefined]) and 33 evaluable patients who achieved 
lesser degrees of clonal response at the same timepoint (median 37.4 months [CI 11.3–
undefined]) (log rank test, p=0.40) (Figure 3a).  Using the ‘percentage of baseline dFLC’ 
method to calculate hematologic response enabled all patients to be considered ‘evaluable’ at 
baseline although, as described above, the 15 patients who did not have a dFLC measurement 
at 3 months were again excluded from this analysis.  Median overall survival among 21 
evaluable patients who achieved a dFLC response of ≥90% within 3 months of baseline was 
undefined compared to 31.8 months (CI 15.7–55.1) among 48 patients who achieved lesser 
degrees of clonal response at the same timepoint (log rank test, p=0.02) (Figure 3b).  There 
was no significant difference in overall survival between those patients who achieved a <50% 
dFLC response at 3 months and those who achieved a dFLC response of 50-89% (log rank test, 
p=0.09) (Figure 3c).  
By Cox regression analysis, independent factors associated with death in the whole 
cohort of 84 patients were elevated NT-proBNP at presentation (HR 2.72 [CI 1.451-5.088], 
p=0.002) and achieving a dLFC response ≥90% at 3 months (HR 0.36 [CI 0.138-0.935], 
p=0.036) (Supplementary Table 1).  Percentage dFLC response was also highly significant 
when incorporated as a continuous variable (HR 0.980 [CI 0.968-0.992], p=0.001) 
 
Renal survival in relation to response to chemotherapy 
Among 68 patients who were dialysis-independent at baseline and therefore evaluable for 
analyses of renal survival, there were 46 patients who were evaluable for hematologic response 
at 3 months according to consensus criteria.  Among 22/46 who achieved an absolute dFLC of 
<40mg/L within 3 months of baseline, median time to dialysis dependence was 9.7 months (CI 
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3.4–undefined) compared to 5.2 months (CI 1.9-17.1) among 24/46 patients who achieved 
lesser degrees of clonal response at the same timepoint (log rank test p=0.18) (Figure 4a).  
Using the ‘percentage of baseline dFLC’ method to calculate hematologic response, there were 
56 patients who were evaluable for hematologic response at 3 months.  Median renal survival 
among 18/56 patients who achieved a dFLC response of ≥90% within 3 months of baseline 
was 23.0 months (CI 9.7–undefined) compared to 6.1 months (CI 3.4-12.5) among 38/56 
patients who achieved lesser degrees of clonal response at the same timepoint (log rank test, 
p=0.003) (Figure 4b).  Renal outcomes were equally poor among those who achieved a delayed 
≥90% dFLC response, classified as only after 6 months from baseline (n=5) or only after 12 
months from baseline (n=6) (dFLC response ≥90% within 3 months vs 6 months (log rank test, 
p=0.001) or vs 12 months (log rank test, p<0.003) (Figure 4c).   
By Cox regression analysis, the only independent factor associated with a requirement 
for RRT among the 68 patients who were dialysis independent at baseline was achieving a 
dFLC response of ≥90% within 3 months (HR 0.24 [CI 0.106-0.547], p=0.001) (Table 2). 
Percentage dFLC response at 3 months was also significant when incorporated as a continuous 
variable (HR 0.978 [CI 0.958-0.998], p=0.031). Interestingly, presenting eGFR, presenting 
NT-proBNP, and proteinuria at presentation did not predict progression to dialysis.  
Furthermore, stratification of patients by index of chronic damage on renal histology was not 
predictive of progression to dialysis, although it should be noted that the vast majority of 
patients had moderate or severe chronic damage on renal biopsy (Table 1).   
Forty-five of 84 patients from the whole cohort had renal amyloidosis in the absence of 
cardiac involvement and were defined as ‘renal isolated.’  Nine such patients were on RRT at 
baseline and 2 died before the 3 month evaluation.  In light of our previous results, the 
remaining 34 ‘evaluable’ patients were stratified using the ‘percentage of baseline dFLC’ 
method to ≥90% or <90% dFLC response within 3 months of baseline.  Median renal survival 
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among 11 patients who achieved a dFLC response of ≥90% within 3 months of baseline was 
23.0 months (CI 7.3–undefined) compared to only 6.2 months (CI 3.0–12.5) among 23 patients 
who achieved lesser degrees of clonal response at the same timepoint (log rank test, p<0.007) 
(Figure 5), and 5.7 months (CI 1.9-undefined) among those who achieved a ≥90% dFLC 
response, but only after 12 months from baseline (log rank test, p<0.03).  There was no 
significant difference in renal survival between those who achieved a dFLC response within 3 
months of 50-89% compared to a dFLC response of <50% (log rank test, p=0.83).  By Cox 
regression analysis, the only independent factor associated with a requirement for RRT in the 
45 patients with ‘renal isolated’ amyloidosis was achieving a dFLC response of ≥90% at 3 
months (HR 0.62 [CI 0.057-0.655], p=0.008).  
 
Time to composite endpoint of death or dialysis in relation to response to chemotherapy 
Sixteen patients, who were dialysis dependent at baseline, were excluded from all analyses of 
time to the composite endpoint of death or dialysis.  Twelve patients did not have an FLC assay 
measured at 3 months from baseline, in 10 cases due to death.  Of the 10 patients who died, 4 
died before receiving chemotherapy, 5 died during chemotherapy from progression of their 
systemic amyloidosis and 1 died from chemotherapy-related complications (sepsis).  The 
remaining 56 patients were stratified according to dFLC response of <90% or ≥90% at 3 
months.  Among 18 patients who achieved a ≥90% dFLC response, median time to composite 
endpoint of death or dialysis was 17.3 months (CI 7.3-46.1) compared to 5.3 months (CI 3.4-
7.6) among 38 patients who achieved a <90% response (log rank test, p<0.001) (Figure 6).  The 
first event was death in 9 patients and dialysis in 27 patients.  There was no significant 
difference in median time to death or dialysis between those patients who achieved a <50% 
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dFLC response at 3 months and those who achieved a dFLC response of 50-89% (log rank test, 
p=0.53).  
By Cox regression analysis, independent factors significantly associated with the 
composite endpoint of death or dialysis among all 68 patients who were dialysis independent 
at baseline were elevated NT-proBNP at presentation (HR 2.40 [CI 1.293-4.463], p=0.006) and 
achieving a dFLC response ≥90% at 3 months (HR 0.23 [CI 0.102-0.505], p<0.001) 
(Supplementary Table 2). Percentage dFLC response was also highly significant when 
incorporated as a continuous variable (HR 0.981 [CI 0.971-0.992], p=0.001). Neither 
presenting eGFR, nor proteinuria at presentation were significant predictors of the composite 
endpoint.  Due to the high clonal response rates observed with bortezomib, a multivariable 
model in which dFLC response at 3 months of <90% or ≥90% was replaced by bortezomib vs 
no bortezomib was undertaken.  The only factor independently associated with the same 
composite endpoint in this model was serum NT-proBNP concentration at presentation (HR 
2.48 [CI 1.350-4.535], p=0.003) (Supplementary Table 2). 
 
Discussion 
Response to chemotherapy is known to be one of the main determinants of patient survival in 
systemic AL amyloidosis.3, 10  Two thirds of patients with systemic AL amyloidosis have renal 
involvement at diagnosis and renal outcome, as well as patient survival, is known to be 
influenced by response to chemotherapy.7  However, no studies have been performed to 
specifically investigate whether the magnitude and speed of clonal response to chemotherapy 
in patients who present with established advanced renal impairment influences time to 
requirement for RRT.  Similarly, the merits of administering chemotherapy, which is invariably 
associated with substantial short-term morbidity, remain uncertain among AL amyloidosis 
10 
 
patients who present with advanced CKD but do not have clinically significant extra-renal 
organ involvement by amyloid.  Here we show for the first time, that the speed and magnitude 
of clonal response in patients presenting with a GFR of <20 ml/min/1.73 m2 due to renal 
amyloidosis, directly influence the clinically important outcome measures of death, dialysis 
and the composite endpoint of death or dialysis, with markedly extended renal and patient 
survival among patients who achieved a clonal response of ≥90% within 3 months of baseline.  
Furthermore, we show that in patients with an eGFR of <20 ml/min/1.73 m2 who do not have 
cardiac amyloidosis, chemotherapy can substantially delay the requirement for RRT.  The 
findings presented here are analogous to the effect of chemotherapy in patients with advanced 
(Mayo stage 3) cardiac AL amyloidosis, 11 in which the speed and depth of clonal response 
directly influence patient survival.  Until now it has not been clear whether the same degree 
and speed of clonal response can salvage renal function or if not, delay RRT in those who do 
not have cardiac involvement and whether patients with isolated renal amyloidosis require 
chemotherapy with the same degree of urgency as those with cardiac AL amyloidosis.   
 Importantly, this study does not prove beyond all doubt that aggressive chemotherapy 
aimed at achieving a rapid and deep clonal response delays dialysis and/or improves survival 
in this cohort of patients, since there was no prospective randomisation to a placebo arm or 
‘low intensity’ chemotherapy arm.  It does not therefore take into account those whose death 
or requirement for RRT may have been accelerated by chemotherapy.  Nonetheless, the 
evidence for pursuing chemotherapy that is likely to achieve a rapid and deep clonal response 
in such patients is compelling; among the 47 patients in the whole cohort who died, 26 did so 
from progressive amyloidosis, including 4 patients who died before receiving chemotherapy; 
with only one death of the 26 deaths attributable to complications of chemotherapy.  Similarly, 
there was no evidence of acute kidney injury complicating CKD among those in the cohort 
who received chemotherapy and only 2 patients out of the 78 who received chemotherapy 
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required discontinuation due to toxicity, one of whom was already receiving RRT at the time 
of commencement of chemotherapy, and the other of whom received a total of 8 cycles (first 
line thalidomide switched to bortezomib) to a complete clonal response and remains dialysis 
independent.  Given that it would probably be considered unethical to withhold chemotherapy 
from patients with advanced renal dysfunction due to AL amyloidosis, particularly in light of 
the findings reported here, a prospective randomised trial to definitively answer this question 
will probably never be possible.   
 Although bortezomib was associated with higher rates of rapid (within 3 months) and 
deep (≥90%) clonal response compared to non-bortezomib containing regimens, we were 
unable to demonstrate that administration of bortezomib was an independent predictor of 
outcome in this cohort.  Nonetheless, we would encourage the use of bortezomib first line in 
patients with advanced renal impairment from AL amyloidosis due to the fact that it is generally 
well tolerated, no dose modification is necessary in patients with advanced renal impairment, 
and due to the speed and efficacy with which it can suppress the underlying clonal dyscrasia.   
 It is noteworthy that use of the established AL amyloidosis consensus criteria for 
measuring clonal response to chemotherapy, in which patients are required to have an absolute 
pre-treatment dFLC concentration of >50 mg/L to be evaluable, was associated with 
categorization of 12% patients as ‘not evaluable’, in accordance with the 15% patients reported 
in the consensus document.12  However, it is interesting that, in this cohort of patients, the 
consensus criteria did not even predict patient survival, which is well known from larger studies 
of patients with AL amyloidosis to be associated with depth of hematologic response at 3 
months.13  However, the ‘percentage of baseline dFLC’ method used in our analyses, which 
has also been previously validated in AL amyloidosis,7 predicted both patient and renal 
survival.  Whilst the consensus criteria may be appropriate for determining eligibility of 
patients with AL amyloidosis for formal clinical trials, our ‘real world’ data indicates that the 
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‘percentage of baseline dFLC’ method is valid and applicable to all patients in a clinical 
practice setting, and may be superior in patients with established advanced CKD.  This study 
is of insufficient size to recommend a change in the consensus criteria, but given the relative 
rarity of the disease, the need for a true representation of clinical practice within clinical trials, 
and the established difficulties associated with enrolling sufficient numbers of patients with 
AL amyloidosis into most clinical trials, we believe that a specific comparison of these two 
methods among a large cohort of AL amyloidosis patients with established advanced CKD is 
warranted and, depending on the findings, may merit considering a change to the consensus 
criteria. 
 In summary, chemotherapy should not be withheld from patients with advanced CKD 
due to renal AL amyloidosis.  On the contrary, such patients should be treated urgently with 
the aim of achieving a rapid and deep clonal response, the result of which may be delayed 
dialysis and prolonged survival.   
 
Patients and Methods 
Patients  
At the time of censor, 1000 patients with newly diagnosed AL amyloidosis had been enrolled 
into the ALchemy prospective observational study at the National Amyloidosis Centre (NAC).  
Renal involvement, defined as non-Bence Jones proteinuria of more than 0.5g/24 hr according 
to the amyloidosis international consensus criteria,14 was present in 672 patients, of whom 84 
had presented with advanced renal impairment defined by eGFR <20 ml/min/1.73 m2.  The 
analyses presented in this manuscript concern this cohort of 84 patients with eGFR 
<20 ml/min/1.73 m2 at baseline (Figure 1; Consort Diagram).   
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All patients underwent protocolized assessments every 3-6 months at the NAC, each 
assessment comprising clinical evaluation, serum and urine biochemistry including assessment 
of renal and liver function, N-terminal pro-b-type natriuretic peptide (NT-proBNP), 
echocardiography, SAP scintigraphy,15 and assessment of hematological disease by serum free 
light chain (FLC) assay, serum and urine immunofixation electrophoresis.  The presence of 
cardiac amyloidosis was defined by echocardiography according to international consensus 
criteria,14 or in cases in which there was doubt, by additional cardiac magnetic resonance 
imaging on the basis of native T1 and/or extracellular volume measurement, as previously 
reported.16, 17 
All patients were managed in accordance with the Declaration of Helsinki and provided 
written informed consent for study entry (REC reference 09/H0715/58) and publication of their 
data. 
 
Renal Histology 
Renal biopsies were performed in 57 of 84 patients.  All biopsies were routinely stained with 
Congo red and a panel of amyloid-fibril antibodies, as previously described.18  Additionally, 
all biopsies containing sufficient cortical tissue for evaluation (n=49/57) were analysed by a 
renal histopathologist (PB) and assigned an ‘Index of Chronic damage’ category of mild, 
moderate or severe according to the previously described Modified Oxford Score.19  
 
Assessment of Hematologic Response 
Details and doses of chemotherapy regimens were collected.  All patients had serial FLC 
concentration prospectively monitored on blood samples scheduled monthly during periods of 
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chemotherapy treatment, and every 1-3 months during subsequent follow up.  Healthy 
polyclonal serum FLC concentrations increase progressively through advancing stages of 
chronic kidney disease (CKD)20 which hinders the monitoring of monoclonal light chain 
disorders.  In this study, the value of the FLC monoclonal component was estimated by 
subtracting the concentration of the uninvolved light chain from that of the amyloidogenic light 
chain to obtain the FLC difference (dFLC), a strategy previously validated in multiple myeloma 
and AL amyloidosis.7, 21   
The FLC response to chemotherapy was determined according to previously validated 
‘consensus criteria’12 and additionally, by the percentage of the baseline dFLC that remained 
at the time of analysis (percentage method), also validated in AL amyloidosis.7  The consensus 
criteria define ‘evaluable’ patients as those with a pre-treatment (baseline) dFLC of >50 mg/L, 
and thus excluded 10/84 (12%) patients in the cohort, whereas the calculation of the percentage 
baseline dFLC remaining after chemotherapy can be applied to patients with low level pre-
treatment amyloidogenic light chain concentration.  A very good partial response (VGPR) was 
defined according to the consensus criteria as an absolute dFLC of <40mg/L, and by the 
percentage method as a ≥90% reduction of pre-treatment dFLC remaining after chemotherapy, 
as previously described.7  When assessing dFLC response, all patients without an FLC assay 
at the relevant timepoint were excluded from analysis.   
 
Patient Outcomes  
Overall survival was defined as the time from baseline evaluation at the NAC to patient death 
and was evaluated in all 84 patients.  Renal survival was defined as the time from baseline 
evaluation at the NAC to requirement for renal replacement therapy (RRT).  For the analyses 
of renal survival, patients who were already established on RRT (n=16) at the time of their 
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baseline evaluation were excluded, and those who died without requiring RRT were censored 
at the time of death.  For analyses of time to the composite endpoint of death or dialysis, patients 
who were on RRT at baseline were excluded and an event was recorded as the first of either 
death or dialysis.  Patient follow up was censored on 1st October 2015. 
 
Statistical Analysis 
Survival analysis was performed separately for each of three possible endpoints: patient 
survival, renal survival, and survival to composite endpoint of dialysis or death. We determined 
Kaplan-Meier curves, and performed the log rank test to compare the overall survival curves 
for different subgroups.  Cox proportional hazards regression analysis was used to investigate 
the factors independently associated with a particular endpoint. A test based on Schoenfeld 
residuals was used to test the proportional hazards assumption underlying the log rank and the 
Cox regression analyses. Analyses were performed using GraphPad Prism v5.03, IBM SPSS 
Statistics 23 and Stata 14 software. A significance level of 0.05 was used for all hypothesis 
tests.   
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Table 1.  Baseline demographics of all patients 
Demographic or clinical characteristic No. of Patients 
(N =84) 
% 
Male sex 
Female sex 
49 
35 
58 
42 
Age years      Median 
      Range 
68 
40-86 
 
Patients with isolated renal involvement 
 
45 54 
Patients presenting on RRT 
 
16 19 
Index of Chronic Damage on renal histology  Mild 
       Moderate 
       Severe 
4/49 
11/49 
34/49 
8 
22 
69 
eGFR (ml/min/1.73 m2)    Median 
       Range 
10 
10-19 
 
Amyloid load by SAP scintigraphy   Small 
      Moderate 
      Large 
27 
19 
38 
32 
23 
45 
Serum albumin (g/L)     Median 
      Range 
31 
14-48 
 
24hr urinary protein loss (g)    Median 
      Range 
6.2 
0.1-29.7 
 
NT-proBNP (pmol/L)     Median 
      Range 
550 
15-8270 
 
Troponin T (ng/L)                                            Median  
                                                                         Range 
120 
10-1870 
 
Amyloidogenic light chain (n)   Lambda 
       Kappa 
55 
29 
65 
35 
Haemoglobin (g/dL)     Median 
      Range 
11.3 
7.8-17 
 
Serum creatinine (µmol/L)    Median  
       Range 
375 
228-979 
 
Bilirubin (µmol/L)     Median 
      Range 
5 
1-59 
 
Alkaline Phosphatase (u/L)    Median 
       Range 
108 
43-1703 
 
Supine systolic blood pressure   Median 
      Range 
137 
79-184 
 
Standing systolic blood pressure   Median 
      Range 
129 
63-180 
 
Bone Marrow Plasmacytosis (%)   Median 
       Range 
7 
0-30 
 
Bence Jones Protein (n)    Present 
       Absent 
44 
40 
 
λ sFLC in AL (lambda) patients (mg/L)  Median 
      Range 
241 
14-5820 
 
Κ sFLC  in AL (kappa) patients (mg/L)  Median 
      Range 
431 
56-10300 
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Table 2.  Independent risk factors associated with dialysis 
Variables 
 
Estimated 
Hazard Ratio  
95% Confidence 
Interval 
p value 
 
dFLC ≥90% at 3 months 
 
0.24 
 
0.106 - 0.547 
 
0.001 
Log NT-proBNP 1.35 0.773 – 2.369 0.289 
eGFR  0.97 0.878 – 1.068 0.564 
Proteinuria 1.01 0.961 – 1.054 0.618 
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Figure Legends 
Figure 1.  Consort Diagram showing selection of patients from the prospective UK AL 
chemotherapy study (ALchemy) for analyses.  Patients in shaded boxes were excluded from 
analyses of renal survival. 
 
Figure 2.  Patient survival calculated by Kaplan Meier analysis in all evaluable patients with 
renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at presentation.  Survival among those 
with ‘renal isolated’ amyloidosis was significantly longer (median 49.2 months) than in those 
with both cardiac and renal (cardio-renal) involvement (median 8.4 months) (p<0.001).  
Number at risk at certain timepoints is shown in panel below graph.   
 
Figure 3.  Patient survival calculated by Kaplan Meier analysis in all evaluable patients with 
renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at presentation.  A)  Patients were 
stratified according to degree of clonal response at 3 months into absolute dFLC <40 mg/L and 
≥40 mg/L (p=0.40).  B)  Patients were stratified according to degree of clonal response at 3 
months into dFLC response ≥90% and dFLC response <90% (p=0.02).  C)  Patients were 
stratified according to degree of clonal response at 3 months into dFLC response of <50% and 
50-89% (p=0.09).  Number at risk at certain timepoints is shown in panel below graph.   
 
Figure 4.  Renal survival calculated by Kaplan Meier analysis in all evaluable patients with 
renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at presentation.  A)  Patients were 
stratified according to degree of clonal response at 3 months into absolute dFLC <40 mg/L and 
≥40 mg/L (p=0.18).  B)  Patients were stratified according to degree of clonal response at 3 
months into dFLC response ≥90% and dFLC response <90% (p=0.003).  C)  Patients were 
stratified according to speed of clonal response comparing those who achieved a dFLC ≥90% 
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within 3 months of baseline with those who achieved an equally good dFLC response, but only 
after 12 months (p<0.003).  Number at risk at certain timepoints is shown in panel below graph.   
 
Figure 5.  Renal survival calculated by Kaplan Meir analysis in evaluable patients with ‘renal 
isolated’ AL amyloidosis and eGFR <20ml/min/1.73 m2 at presentation.  Patients were 
stratified according to degree of clonal response at 3 months into dFLC response ≥90% and 
dFLC response <90% (p<0.007).  Number at risk at certain timepoints is shown in panel below 
graph.   
 
Figure 6.  Time to composite endpoint of death or dialysis calculated by Kaplan Meier analysis 
in all evaluable patients with renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at 
presentation, stratified according to degree of clonal response at 3 months into dFLC response 
≥90% and dFLC response <90% (p<0.001).  Number at risk at certain timepoints is shown in 
panel below graph.   
 
